Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Deep learning method maps spatial architecture of brain cancer cells

Glioblastoma is the deadliest and most common type of malignant brain tumour in adults. One of the reasons it's almost always incurable is that individual tumour cells are very different from one another and shift dynamically between various 'states'.

4 Nov 2026

Space-grown organoids better replicate aggressive glioblastoma tumors

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and is one of the most aggressive and deadly forms of cancer.

30 Oct 2026

Platelet hyperactivity drives glioblastoma progression and deep vein thrombosis

New Cleveland Clinic research published in Cancer Cell shows that people with glioblastoma have more active platelets, which are cells involved in blood clotting. Platelets also communicate with other cells and can influence immune activity. The overactive platelets in people with glioblastoma slow the activity of cancer-fighting T cells, which can contribute to tumor growth and cancer progression.

30 Oct 2026

UCSF scientists develop smart CAR-T cells to fight childhood brain tumors

Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells.

28 Oct 2026

Baylor researchers discover how glioblastoma hijacks nearby brain cells

Researchers at Baylor College of Medicine have discovered a new strategy that glioblastoma, the most common and aggressive form of adult brain cancer, uses to fuel its own growth.

27 Oct 2026

Blocking cellular communication reduces the spread of deadly glioblastoma

In a new study published in Cancer Cell, researchers at VIB-KU Leuven reduced the spread of glioblastoma by interrupting specific interactions between the brain's immune cells and tumor cells.

27 Oct 2026

Implantable drug-delivery device could help prevent recurrence of glioblastoma

Patients with glioblastoma, an aggressive type of brain tumor, usually undergo surgery to remove the tumor. However, it's difficult for surgeons to remove all of the cancer cells, and the tumor often recurs.

26 Oct 2026

Altered fatty acid metabolism drives glioblastoma growth and treatment resistance

Glioma is the most common primary malignant brain tumor in adults, and glioblastoma (GBM), particularly IDH (Isocitrate dehydrogenase)-wildtype disease, has the poorest prognosis.

21 Oct 2026

New review highlights expanding potential of therapeutic DNA vaccines

A new review published in Genes & Diseases highlights the expanding potential of DNA-based vaccines as a flexible platform for preventing infectious diseases, treating cancer and strengthening preparedness for future disease outbreaks.

12 Oct 2026

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.

9 Oct 2026

Combination therapy overcomes immunotherapy resistance in glioblastoma

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.

8 Oct 2026

Experimental cancer drug works differently than researchers originally thought

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

6 Oct 2026

AI-based model predicts glioblastoma recurrence to guide targeted treatment

A new AI-based model can predict where glioblastoma is most likely to return after initial surgery, potentially giving doctors a chance to treat it before it becomes visible on MRI.

25 Sep 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

JMIR Publications: Emerging health tech trends

JMIR Publications released three feature News and Perspectives articles this week, covering an emerging application of drone delivery, the implications of AI tools used in early education, the nascent field of cancer neurotech, and the future of consumer wearable devices.

4 Sep 2026